This trial has been completed.

Condition alzheimer's disease
Treatment donepezil hydrochloride
Sponsor Eisai Co., Ltd.
Start date June 2013
End date May 2015
Trial size 8662 participants
Trial identifier NCT02162264, ART08T


To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
donepezil hydrochloride Aricept
Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.

Primary Outcomes

Change From Baseline in the Mini-Mental State Examination (MMSE) Score
time frame: Baseline, Month 3, Month 6, and Month 12

Secondary Outcomes

Investigations on adverse events and adverse drug reactions
time frame: Baseline and Month 12

Eligibility Criteria

All participants of any age.

Inclusion criteria: Patients diagnosed with Alzheimer's Disease and administered Aricept for the first time. Exclusion criteria: Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.

Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Eisai Inc..